HRT Formulary (HP160)

HRT Formulary (HP160)

HRT Formulary (HP160)

Overview/Purpose

This protocol guides the user through the prescription of appropriate HRT for the patient being reviewed.

Resource type:

Base
Optional
Localised
✔


Product

This protocol alert is part of the PCIT toolset product

What does it do?

This protocol takes account of:

  1. Patients with hysterectomy
  2. Patients with mirena fitted
  3. Patients who are peri-menopausal
  4. Patients who are post-menopausal
and guides many options for HRT prescribing.

Why is it important?

Prescribing of HRT is often a challenge for clinicians who don't prescribe it regularly.  Remembering the different formulations available can be a challenge.  Equally it is important to ensure progesterone is provided for uterine protection where needed.

What does it look like?

The link for out of stock checking is shown initially:


The patient is checked to see if they need uterine protection with progesterone and the information confirmed with the user:


It it established if the patient is within 12 months of their last period:


The user is offered a choice of formulations:


When an option is chosen (in this case gel HRT), further options are shown:


The choice is then added:


and then offered for issue:


 The user is guided through any other prescriptions required:


If an option to prescribe is chosen this is added:


and then offered for issue:


Users are then reminded about Genitourinary Syndrome of the Menopause and asked if they wish to prescribe, if they do they are guided through the options:


How to get it

This is a base handy protocol and will be installed in all sites.  If you can't see this within your system please click here to submit a ticket.

FAQs


System Triggers

System trigger: Manual launch (via OneLauncher Prescriber)

Change management considerations

Your team need to be aware that this protocol is available to guide them through prescribing of HRT.

HP current version number: 7.0.0

Changelog

7.0.0 25/3/24
Updated to include a number of useful links for menopausal women at the outset.
Micronised progesterone offered as first line option.
Premique and Premarin removed.
Transdermal options for oestrogen offered first as doesn't increase clot risk and safer than oral oestrogen.
Options added for different dosing of oestrogen gel.
Utrogestogen dosing instructions updated to current guidelines.
Changed language to be gender-neutral.

    • Related Articles

    • OneLauncher NonPrescriber

      Information within this training package is colour coded: Blue is for information and includes hints and tips Orange is an action that is required Yellow is resource that you can use to send internal communications to others within your practice Red ...

    • OneLauncher Prescriber

      Introduction The OneLauncher Prescriber tool brings together all of the tools that are relevant for Prescribers into one easy place so you can easily locate and use the powerful tools that we've created for you. As further tools are developed, these ...

    • OneLauncher Additional Roles

      Overview The OneLauncher Additional Roles encompasses our resources which are useful to the Additional Roles Reimbursement Scheme (ARRS) associates and clinicians. The launcher allows the user to easily access these resources from one place. The ...

    • Foundry RAG system (HP219 and HP220)

      Foundry RAG system (HP219 and HP220) Overview/Purpose These resources comprise of a protocol alert (Foundry alerts system HP219) and a protocol (Foundry consultation closer HP220). The protocol alert (HP219) shows the RAG status for the patient you ...

    • Sick Day Rules (HP026)

      Sick Day Rules (HP026) Overview/Purpose This is a protocol alert which alerts the user of patients who should be given information about Sick Day Rules. The alert identifies patients on specific medications that require sick day rules guidance. It ...